AAPL323.81+8.47 (+2.69%) ▲|ABBV252.61+1.70 (+0.68%) ▲|ABT103.82-1.42 (-1.34%) ▼|ACN177.64+1.84 (+1.05%) ▲|ADBE249.37-5.49 (-2.15%) ▼|AMAT457.63-11.22 (-2.39%) ▼|AMD506.42-14.68 (-2.82%) ▼|AMGN382.73-8.54 (-2.18%) ▼|AMT172.86-2.57 (-1.47%) ▼|AMZN252.26-0.15 (-0.06%) ▼|AVGO362.82-1.56 (-0.43%) ▼|AXP320.69-1.12 (-0.35%) ▼|BA206.24-0.18 (-0.09%) ▼|BAC62.40-0.28 (-0.44%) ▼|BKNG175.74+2.31 (+1.33%) ▲|BLK1,069.35-2.69 (-0.25%) ▼|BMY63.95-0.46 (-0.71%) ▼|BNY162.29-0.22 (-0.14%) ▼|BRK-B504.93-1.79 (-0.35%) ▼|C137.99+0.19 (+0.14%) ▲|CAT802.09-13.48 (-1.65%) ▼|CL88.23+0.20 (+0.23%) ▲|CMCSA25.15+0.56 (+2.26%) ▲|COF207.55-3.31 (-1.57%) ▼|COP137.88+1.35 (+0.99%) ▲|COST899.44-3.16 (-0.35%) ▼|CRM244.04-0.12 (-0.05%) ▼|CSCO108.19-1.24 (-1.13%) ▼|CVS95.24-0.14 (-0.15%) ▼|CVX213.52-0.30 (-0.14%) ▼|DE674.07-3.14 (-0.46%) ▼|DHR201.69-3.17 (-1.55%) ▼|DIS104.89+0.71 (+0.68%) ▲|DUK119.64-0.80 (-0.66%) ▼|EMR147.52-2.83 (-1.88%) ▼|FDX311.06+1.87 (+0.60%) ▲|GD353.48+0.81 (+0.23%) ▲|GE322.87-2.55 (-0.78%) ▼|GEV925.75-25.29 (-2.66%) ▼|GILD145.05-0.60 (-0.41%) ▼|GM85.49+1.73 (+2.07%) ▲|GOOG329.31+0.93 (+0.28%) ▲|GOOGL331.57+0.92 (+0.28%) ▲|GS1,020.01-8.77 (-0.85%) ▼|HD305.21-5.24 (-1.69%) ▼|HON202.18-2.76 (-1.34%) ▼|IBM236.33-3.62 (-1.51%) ▼|INTC101.37-4.87 (-4.58%) ▼|INTU312.62-1.32 (-0.42%) ▼|ISRG360.15+6.91 (+1.96%) ▲|JNJ266.75-0.34 (-0.13%) ▼|JPM352.80-1.91 (-0.54%) ▼|KO88.14+0.59 (+0.67%) ▲|LIN461.61-5.05 (-1.08%) ▼|LLY1,126.61+2.40 (+0.21%) ▲|LMT528.21+3.75 (+0.72%) ▲|LOW195.79-2.82 (-1.42%) ▼|LRCX300.79-15.05 (-4.77%) ▼|MA564.19-3.32 (-0.58%) ▼|MCD253.70+0.22 (+0.08%) ▲|MDLZ62.26-0.16 (-0.26%) ▼|MDT91.36-0.53 (-0.58%) ▼|META649.75-3.94 (-0.60%) ▼|MMM162.34-2.06 (-1.25%) ▼|MO68.67+0.78 (+1.14%) ▲|MRK145.04-2.50 (-1.69%) ▼|MS213.84-1.51 (-0.70%) ▼|MSFT492.38+0.73 (+0.15%) ▲|MU979.91-47.87 (-4.66%) ▼|NEE82.55-0.10 (-0.12%) ▼|NFLX75.99-0.05 (-0.06%) ▼|NKE36.81-0.54 (-1.45%) ▼|NOW131.94+0.83 (+0.63%) ▲|NVDA218.46-5.21 (-2.33%) ▼|ORCL156.58-5.05 (-3.12%) ▼|PEP136.89+0.20 (+0.15%) ▲|PFE27.51-0.28 (-0.99%) ▼|PG142.91+0.27 (+0.19%) ▲|PLTR166.14-3.39 (-2.00%) ▼|PM189.15+3.44 (+1.85%) ▲|QCOM180.12+3.72 (+2.11%) ▲|RTX197.41-0.14 (-0.07%) ▼|SBUX99.65-0.39 (-0.39%) ▼|SCHW106.74+0.20 (+0.18%) ▲|SO87.91-0.44 (-0.49%) ▼|SPG205.94+1.41 (+0.69%) ▲|T25.53+0.38 (+1.49%) ▲|TMO603.01-2.68 (-0.44%) ▼|TMUS175.87-1.47 (-0.83%) ▼|TSLA366.60-1.21 (-0.33%) ▼|TXN259.47-2.12 (-0.81%) ▼|UBER72.45+1.37 (+1.93%) ▲|UNH390.92-2.14 (-0.54%) ▼|UNP284.23-0.52 (-0.18%) ▼|UPS100.08+0.86 (+0.86%) ▲|USB62.01-0.11 (-0.17%) ▼|V366.59-0.80 (-0.22%) ▼|VZ49.92+0.18 (+0.36%) ▲|WFC88.94-0.74 (-0.82%) ▼|WMT105.89+0.06 (+0.05%) ▲|XOM165.42+1.19 (+0.72%) ▲|AAPL323.81+8.47 (+2.69%) ▲|ABBV252.61+1.70 (+0.68%) ▲|ABT103.82-1.42 (-1.34%) ▼|ACN177.64+1.84 (+1.05%) ▲|ADBE249.37-5.49 (-2.15%) ▼|AMAT457.63-11.22 (-2.39%) ▼|AMD506.42-14.68 (-2.82%) ▼|AMGN382.73-8.54 (-2.18%) ▼|AMT172.86-2.57 (-1.47%) ▼|AMZN252.26-0.15 (-0.06%) ▼|AVGO362.82-1.56 (-0.43%) ▼|AXP320.69-1.12 (-0.35%) ▼|BA206.24-0.18 (-0.09%) ▼|BAC62.40-0.28 (-0.44%) ▼|BKNG175.74+2.31 (+1.33%) ▲|BLK1,069.35-2.69 (-0.25%) ▼|BMY63.95-0.46 (-0.71%) ▼|BNY162.29-0.22 (-0.14%) ▼|BRK-B504.93-1.79 (-0.35%) ▼|C137.99+0.19 (+0.14%) ▲|CAT802.09-13.48 (-1.65%) ▼|CL88.23+0.20 (+0.23%) ▲|CMCSA25.15+0.56 (+2.26%) ▲|COF207.55-3.31 (-1.57%) ▼|COP137.88+1.35 (+0.99%) ▲|COST899.44-3.16 (-0.35%) ▼|CRM244.04-0.12 (-0.05%) ▼|CSCO108.19-1.24 (-1.13%) ▼|CVS95.24-0.14 (-0.15%) ▼|CVX213.52-0.30 (-0.14%) ▼|DE674.07-3.14 (-0.46%) ▼|DHR201.69-3.17 (-1.55%) ▼|DIS104.89+0.71 (+0.68%) ▲|DUK119.64-0.80 (-0.66%) ▼|EMR147.52-2.83 (-1.88%) ▼|FDX311.06+1.87 (+0.60%) ▲|GD353.48+0.81 (+0.23%) ▲|GE322.87-2.55 (-0.78%) ▼|GEV925.75-25.29 (-2.66%) ▼|GILD145.05-0.60 (-0.41%) ▼|GM85.49+1.73 (+2.07%) ▲|GOOG329.31+0.93 (+0.28%) ▲|GOOGL331.57+0.92 (+0.28%) ▲|GS1,020.01-8.77 (-0.85%) ▼|HD305.21-5.24 (-1.69%) ▼|HON202.18-2.76 (-1.34%) ▼|IBM236.33-3.62 (-1.51%) ▼|INTC101.37-4.87 (-4.58%) ▼|INTU312.62-1.32 (-0.42%) ▼|ISRG360.15+6.91 (+1.96%) ▲|JNJ266.75-0.34 (-0.13%) ▼|JPM352.80-1.91 (-0.54%) ▼|KO88.14+0.59 (+0.67%) ▲|LIN461.61-5.05 (-1.08%) ▼|LLY1,126.61+2.40 (+0.21%) ▲|LMT528.21+3.75 (+0.72%) ▲|LOW195.79-2.82 (-1.42%) ▼|LRCX300.79-15.05 (-4.77%) ▼|MA564.19-3.32 (-0.58%) ▼|MCD253.70+0.22 (+0.08%) ▲|MDLZ62.26-0.16 (-0.26%) ▼|MDT91.36-0.53 (-0.58%) ▼|META649.75-3.94 (-0.60%) ▼|MMM162.34-2.06 (-1.25%) ▼|MO68.67+0.78 (+1.14%) ▲|MRK145.04-2.50 (-1.69%) ▼|MS213.84-1.51 (-0.70%) ▼|MSFT492.38+0.73 (+0.15%) ▲|MU979.91-47.87 (-4.66%) ▼|NEE82.55-0.10 (-0.12%) ▼|NFLX75.99-0.05 (-0.06%) ▼|NKE36.81-0.54 (-1.45%) ▼|NOW131.94+0.83 (+0.63%) ▲|NVDA218.46-5.21 (-2.33%) ▼|ORCL156.58-5.05 (-3.12%) ▼|PEP136.89+0.20 (+0.15%) ▲|PFE27.51-0.28 (-0.99%) ▼|PG142.91+0.27 (+0.19%) ▲|PLTR166.14-3.39 (-2.00%) ▼|PM189.15+3.44 (+1.85%) ▲|QCOM180.12+3.72 (+2.11%) ▲|RTX197.41-0.14 (-0.07%) ▼|SBUX99.65-0.39 (-0.39%) ▼|SCHW106.74+0.20 (+0.18%) ▲|SO87.91-0.44 (-0.49%) ▼|SPG205.94+1.41 (+0.69%) ▲|T25.53+0.38 (+1.49%) ▲|TMO603.01-2.68 (-0.44%) ▼|TMUS175.87-1.47 (-0.83%) ▼|TSLA366.60-1.21 (-0.33%) ▼|TXN259.47-2.12 (-0.81%) ▼|UBER72.45+1.37 (+1.93%) ▲|UNH390.92-2.14 (-0.54%) ▼|UNP284.23-0.52 (-0.18%) ▼|UPS100.08+0.86 (+0.86%) ▲|USB62.01-0.11 (-0.17%) ▼|V366.59-0.80 (-0.22%) ▼|VZ49.92+0.18 (+0.36%) ▲|WFC88.94-0.74 (-0.82%) ▼|WMT105.89+0.06 (+0.05%) ▲|XOM165.42+1.19 (+0.72%) ▲|
30.6 C
New York
Thursday, September 10, 2026

Tag: months

newssourceFORcompanyinformationcontent1releasesmarket

Trump Boasts China Breakthrough—Details as Solid as a Politician’s Promise

In the theater of global economics, where every act is a grand spectacle of diplomatic pantomime, we now have the latest episode starring the...

Tokyo Gas Wins CNCF End User Case Study Contest for Driving Cloud Native Agility with Kubernetes, Argo and Istio

Company to present digital platform modernization success at KubeCon + CloudNativeCon Japan 2025 TOKYO, June 15, 2025 /PRNewswire/ -- The Cloud Native Computing Foundation® (CNCF®), which...

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  presented the subgroup analysis data from the Phase III COMPASSION-16...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

China Trade ‘Deal’: U.S. Masterclass in Running Circles

In the grand theater of global economics, the U.S. and China have once again graced us with a riveting episode of "Let's Pretend We're...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Scatec reaches financial close for the 1.1GW solar + 100MW/200MWh BESS Obelisk project

Oslo/Cairo, 15 June 2025: Scatec ASA has reached financial close for the “Obelisk” hybrid solar and battery storage project in Egypt.

Zilliz Transforms Video Surveillance Industry with AI-Powered Vector Database Solutions

Leading surveillance providers leverage Zilliz Cloud to overcome data overload challenges, enabling real-time threat detection and sub-second video search across enterprise installations. REDWOOD SHORES, Calif.,...

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Rocket Pharmaceuticals, Inc. and Encourages Investors to...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ:RCKT) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Rocket securities between February 27, 2025 to May 26, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Rivalry Provides Update on Management Cease Trade Order

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Rivalry Corp. (the “Company” or “Rivalry”) (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), is providing this bi-weekly update on the status of a management cease trade order granted on May 1, 2025 (the "MCTO") by its principal regulator, the Ontario Securities Commission (the "OSC"), under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"). On May 2, 2025, the Company announced that there would be a delay in the filing of its annual financial statements, management’s discussion and analysis and related CEO and CFO certificates for the fiscal year ended December 31, 2024 (collectively, the “Annual Filings”), as required under applicable Canadian securities laws (the "Default Announcement"). As stated in the Default Announcement, the Company expects to complete the Annual Filings by June 30, 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMonths

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers